Evaluation of a hypertension medication therapy management program in patients with diabetes

Journal of the American Pharmacists Association

Volumn 49, Issue 2, 2009, Pages 164-170

  Planas, Lourdes G ^a   Crosby, Kimberly M ^b,c   Mitchell, Kimberly D ^c,d   Farmer, Kevin C ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c USA Drug Stores   (United States)

^d SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Adherence; Blood pressure; Community pharmacy; Diabetes; Hypertension; Interventions; Medication therapy management

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; PHARMACY; RANDOMIZED CONTROLLED TRIAL; STANDARD; STATISTICS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; COMMUNITY PHARMACY SERVICES; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; PATIENT COMPLIANCE; QUALITY OF HEALTH CARE; TREATMENT OUTCOME;

EID: 67449099380     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2009.08164     Document Type: Article

References (28)

1. Ong KL, Cheung BMY, Man YB et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.
3. Parving HH. Controlling hypertension in diabetes. Acta Diabetol. 2002;39(suppl 2):S35-40.
4. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.
5. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(suppl 1):S12-54.
6. Ong KL, Cheung BMY, Wong LYF, et al. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol. 2008;18:222-9.
7. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
8. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-9.
9. Park JJ, Kelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc. 1996;NS36:443-51.
10. Carter BL, Barnette DJ, Chrischilles E, et al. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy. 1997;17:1274-85.
11. Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy. 1997;17:140-7.
12. Chabot I, Moisan J, Gregoire JP, Milot A. Pharmacist intervention program for control of hypertension. Ann Pharmacother. 2003;37:1186-93.
13. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc. 2008;48:23-31.
14. Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. int J Clin Pract. 2008;62:76-87.
15. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42:200-9.
16. Ho PM, Magid DJ, Shetterly SM, et al. importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch intern Med. 2008;168:271-6.
17. American Diabetes Association. Clinical practice recommendations 2005. Diabetes Care. 2005;28(suppl 1):S1-79.
18. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-16.
19. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32:636-41.
20. Gerber RA, Liu G, McCombs JS. Impact of pharmacist consultations provided to patients with diabetes on healthcare costs in a health maintenance organization. Am J Manag Care. 1998;4:991-1000.
21. Berringer R, Shibley MC, Cary CC, et al. Outcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Assoc. 1999;39:791-7.
22. Nau DP, Ponte CD. Effects of a community pharmacist-based diabetes patient-management program on intermediate clinical outcome measures. J Manag Care Pharm. 2002;8:48-53.
23. Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:149-59.
24. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173-84.
25. Irons BK, Lenz RJ, Anderson SL, et al. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy. 2002;22:1294-300.
26. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-62.
27. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-53.
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.